Algorae Pharmaceuticals Overview

  • Year Founded
  • 1987

Year Founded

  • Status
  • Public

  • Employees
  • 48

Employees

  • Stock Symbol
  • 1AI

Stock Symbol

  • Investments
  • 2

Algorae Pharmaceuticals General Information

Description

Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met medical needs in the community. The firm develops AlgoraeOS, a closed-loop platform, leveraging computational tools to generate novel insights in silico that are being developed to initiate or accelerate therapeutic programs. The products of the company comprise AI-116, a novel combination drug candidate of cannabidiol (CBD) and an off-patent pharmaceutical ingredient. The company is conceptualized to be a potential treatment for dementia, including Alzheimer's disease, NTCELL is an alginate-coated capsule containing clusters of neonatal porcine choroid plexus cells. It also offers LP-003 Anti-obesity Drug and LC-002 migraine treatment.

Contact Information

Formerly Known As
Diatranz, Living Cell Technologies
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Level 23, Rialto South Tower
  • 525 Collins Street
  • Melbourne, Victoria 3000
  • Australia
+61 1300
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
ASX
Vertical(s)
Corporate Office
  • Level 23, Rialto South Tower
  • 525 Collins Street
  • Melbourne, Victoria 3000
  • Australia
+61 1300

Algorae Pharmaceuticals Timeline

2022202320242025
Financing Round

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Algorae Pharmaceuticals Stock Performance

As of 10-Feb-2025, Algorae Pharmaceuticals’s current market cap is $6.86M with 1.69B shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.86M 1.69B 1.05M

Algorae Pharmaceuticals Financials Summary

As of 31-Dec-2024, Algorae Pharmaceuticals has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 31-Dec-2024 FY 2024 30-Jun-2024 FY 2023 30-Jun-2023 FY 2022 30-Jun-2022
EV 4,218 8,754 12,769 4,158
EBITDA (1,455) (1,445) (1,721)
Net Income (1,373) (1,417) (1,418)
Total Assets 2,134 2,788 2,940
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Algorae Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Algorae Pharmaceuticals‘s full profile, request access.

Request a free trial

Algorae Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Algorae Pharmaceuticals Ltd is a clinical-stage pharmaceutical company developing transformative solutions for under met
Biotechnology
Melbourne, Australia
48 As of 2008

Germantown, MD
 

Lexington, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Algorae Pharmaceuticals Competitors (3)

One of Algorae Pharmaceuticals’s 3 competitors is Orgenesis, a Corporation company based in Germantown, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Orgenesis Corporation Germantown, MD
Agenus Formerly VC-backed Lexington, MA
Lineage Cell Therapeutics Corporation Carlsbad, CA
You’re viewing 3 of 3 competitors. Get the full list »

Algorae Pharmaceuticals Patents

Algorae Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2007200990-B2 Cell implantation to prevent and/or treat hearing loss Inactive 21-Nov-2006
US-20080119909-A1 Cell implantation to prevent and/or treat hearing loss Inactive 21-Nov-2006
AU-2009202749-A1 Cell implantation to prevent and/or treat hearing loss Active 21-Nov-2006
US-20150164990-A1 Compositions and methods for preventing and/or treating sensorineural hearing loss Inactive 21-Nov-2006
AU-2009202749-B2 Cell implantation to prevent and/or treat hearing loss Inactive 21-Nov-2006 A61K35/30
To view Algorae Pharmaceuticals’s complete patent history, request access »

Algorae Pharmaceuticals Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Algorae Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Algorae Pharmaceuticals‘s full profile, request access.

Request a free trial

Algorae Pharmaceuticals Investments (2)

Algorae Pharmaceuticals’s most recent deal was a Joint Venture with Diatranz Otsuka. The deal was made on 01-Nov-2011.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Diatranz Otsuka 01-Nov-2011 Joint Venture Drug Discovery
CytoSolv 09-Feb-2010 Seed Round Biotechnology
To view Algorae Pharmaceuticals’s complete investments history, request access »

Algorae Pharmaceuticals ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view Algorae Pharmaceuticals’s complete esg history, request access »

Algorae Pharmaceuticals Exits (2)

Algorae Pharmaceuticals’s most recent exit was on 01-Nov-2011 from Diatranz Otsuka. The exit was categorized as with 2 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
Diatranz Otsuka 01-Nov-2011 Completed
  • 2 buyers
CytoSolv 09-Feb-2010 Seed Round Completed
  • 2 buyers
To view Algorae Pharmaceuticals’s complete exits history, request access »

Algorae Pharmaceuticals FAQs

  • When was Algorae Pharmaceuticals founded?

    Algorae Pharmaceuticals was founded in 1987.

  • Where is Algorae Pharmaceuticals headquartered?

    Algorae Pharmaceuticals is headquartered in Melbourne, Australia.

  • What is the size of Algorae Pharmaceuticals?

    Algorae Pharmaceuticals has 48 total employees.

  • What industry is Algorae Pharmaceuticals in?

    Algorae Pharmaceuticals’s primary industry is Biotechnology.

  • Is Algorae Pharmaceuticals a private or public company?

    Algorae Pharmaceuticals is a Public company.

  • What is Algorae Pharmaceuticals’s stock symbol?

    The ticker symbol for Algorae Pharmaceuticals is 1AI.

  • What is the current market cap of Algorae Pharmaceuticals?

    The current market capitalization of Algorae Pharmaceuticals is $6.86M.

  • Who are Algorae Pharmaceuticals’s competitors?

    Orgenesis, Agenus, and Lineage Cell Therapeutics are competitors of Algorae Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »